Tzu-Fei Wang: Drug–Drug Interactions Between DOACs and Prostate Cancer Therapies
Tzu-Fei Wang, Associate Professor at University of Ottawa, The Ottawa Hospital, and The Ottawa Hospital Research Institute, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Cancer, adding:
“Concerned about drug – drug interactions between DOACs and prostate cancer therapies?
New study of 2,297 patients from Ontario and Alberta:
No increase in thrombosis with DOACs and enzalutamide or apalutamide
No increase in bleeding with DOAC and abiraterone
Reassuring real-world data for clinicians to guide anticoagulation!”
Title: Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents
Authors: Tzu-Fei Wang, Anna Clarke, Mitchell Rath, Samantha Yoo, Deena Fremont , Cynthia Wu , Pietro Ravani , Dominick Bossé , Robert Talarico, Marc Carrier , Manish M. Sood
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 20, 2026, 15:30Abinash Choudhury: A Mother’s Advocacy Transforming Hemophilia Care in Nigeria
-
Apr 20, 2026, 15:30Kalyan Roy: A Critical Safety Intervention in Transfusion Medicine
-
Apr 20, 2026, 15:23Bruno Lacombe: Experiencing a “A Life in a Day” with Hemophilia in Japan
-
Apr 20, 2026, 15:20Eman Hassan: New Insight into AF and VTE at BSH 2026
-
Apr 20, 2026, 15:12Tushar Pandey: From ITP to TTP in Clinical Practice
-
Apr 20, 2026, 15:03Wolfgang Miesbach: The Most Underappreciated Challenges in Haemophilia Care Tackled at WFH 2026
-
Apr 20, 2026, 15:03Danielle Boyle: Patient Voices Transform Progress in ITP Research and Care with ISTH
-
Apr 20, 2026, 14:48Melissa Hollo: Intravenous Iron Shows Better Results Than Oral Iron in Pregnancy
-
Apr 20, 2026, 14:46Annalisa Paviglianiti: Real-World Outcomes of Maribavir for CMV After Hematopoietic Cell Transplantation